Atrasentan hydrochloride is under clinical development by Chinook Therapeutics and currently in the Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Atrasentan hydrochloride’s likelihood of approval (LoA) and phase transition for Alport Syndrome took place on 07 Nov 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 07 Nov 2022 increased Atrasentan hydrochloride’s Phase Transition Success Rate (PTSR) for Focal Segmental Glomerulosclerosis (FSGS).

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Atrasentan hydrochloride Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Atrasentan hydrochloride overview

Atrasentan hydrochloride (ABT-627) is under development for the treatment of immunoglobulin A nephropathy and proteinuric glomerular diseases including focal segmental glomerulosclerosis (FSGS), alport syndrome and diabetic kidney disease (DKD). The drug candidate is administered orally. The drug candidate selectively targets endothelin-A receptor. It was also under development for the treatment of diabetic nephropathy associated with chronic kidney disease, pediatric nephrotic syndrome, metastatic hormone-refractory prostate cancer, hypertension, diabetic neuropathic pain and ovarian cancer

Chinook Therapeutics overview

Chinook Therapeutics, Inc (Chinook)., formerly Aduro BioTech Inc is a clinical-stage immunotherapy company that discovers, develops and commercializes therapies for the treatment of cancer. The company develops product candidates using proprietary technology platforms such as live, attenuated, double-deleted listeria, sting pathway activators; and B-select monoclonal antibodies to create immunotherapies for the treatment of cancers, infectious and autoimmune diseases. Its products are under development and are intended for the treatment of variety of cancers, including metastatic colorectal, multiple myeloma cancers, as well as other solid tumors and lymphomas. The company collaborates with various pharmaceutical companies to expand its products, and technology platforms. It has an operational presence in The Netherlands. Chinook is headquartered in Berkeley, California, the US.

Quick View Atrasentan hydrochloride LOA Data

Report Segments
  • Innovator
Drug Name
  • Atrasentan hydrochloride
Administration Pathway
  • Oral
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
  • Genetic Disorders
  • Genito Urinary System And Sex Hormones
  • Metabolic Disorders
  • Oncology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.